Free Trial

Traws Pharma (TRAW) Competitors

0.00 (0.00%)
(As of 05/20/2024 ET)


Should you be buying Traws Pharma stock or one of its competitors? The main competitors of Traws Pharma include Aytu BioPharma (AYTU), NeuroSense Therapeutics (NRSN), Flora Growth (FLGC), Galecto (GLTO), iBio (IBIO), Kiora Pharmaceuticals (KPRX), Minerva Neurosciences (NERV), Vincerx Pharma (VINC), Edesa Biotech (EDSA), and VBI Vaccines (VBIV). These companies are all part of the "pharmaceutical preparations" industry.

Traws Pharma vs.

Traws Pharma (NASDAQ:TRAW) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, community ranking, dividends, media sentiment and earnings.

Aytu BioPharma has higher revenue and earnings than Traws Pharma. Aytu BioPharma is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Traws Pharma$230K70.37-$18.95M-$0.87-0.74
Aytu BioPharma$107.40M0.16-$17.05M-$2.63-1.17

Traws Pharma has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of -1.23, indicating that its stock price is 223% less volatile than the S&P 500.

In the previous week, Aytu BioPharma had 3 more articles in the media than Traws Pharma. MarketBeat recorded 5 mentions for Aytu BioPharma and 2 mentions for Traws Pharma. Traws Pharma's average media sentiment score of 1.00 beat Aytu BioPharma's score of 0.72 indicating that Traws Pharma is being referred to more favorably in the media.

Company Overall Sentiment
Traws Pharma Positive
Aytu BioPharma Positive

8.0% of Traws Pharma shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 3.3% of Traws Pharma shares are owned by insiders. Comparatively, 2.8% of Aytu BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Aytu BioPharma has a consensus target price of $5.00, suggesting a potential upside of 62.34%. Given Aytu BioPharma's higher probable upside, analysts plainly believe Aytu BioPharma is more favorable than Traws Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Traws Pharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
Aytu BioPharma
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)

Aytu BioPharma has a net margin of -14.60% compared to Traws Pharma's net margin of -8,033.63%. Aytu BioPharma's return on equity of -31.31% beat Traws Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Traws Pharma-8,033.63% -144.95% -73.83%
Aytu BioPharma -14.60%-31.31%-7.99%

Aytu BioPharma received 255 more outperform votes than Traws Pharma when rated by MarketBeat users.

Traws PharmaN/AN/A
Aytu BioPharmaOutperform Votes
Underperform Votes


Aytu BioPharma beats Traws Pharma on 10 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TRAW vs. The Competition

MetricTraws PharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$16.18M$6.84B$5.02B$7.99B
Dividend YieldN/A2.72%45.43%3.91%
P/E Ratio-0.7418.56160.9417.92
Price / Sales70.37253.502,490.5772.59
Price / CashN/A20.3832.6029.27
Price / Book1.
Net Income-$18.95M$142.23M$102.68M$212.94M
7 Day Performance-0.91%2.42%1.65%2.60%
1 Month Performance-4.52%5.18%5.60%6.91%
1 Year PerformanceN/A-3.84%7.26%9.89%

Traws Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
Aytu BioPharma
3.2489 of 5 stars
+59.6%$16.38M$107.40M-1.12150Earnings Report
NeuroSense Therapeutics
0 of 5 stars
N/A-27.2%$16.67MN/A-1.4618News Coverage
Gap Up
Flora Growth
3.11 of 5 stars
-76.3%$16.79M$76.07M0.0097Earnings Report
Analyst Revision
News Coverage
Gap Up
1.0905 of 5 stars
0 of 5 stars
N/AN/A$17.07M$2.38M0.0026Gap Up
Kiora Pharmaceuticals
2.4026 of 5 stars
N/A-71.1%$14.97M$16M0.0012Analyst Forecast
News Coverage
Minerva Neurosciences
3.3322 of 5 stars
-63.0%$17.62MN/A-0.569Analyst Forecast
Vincerx Pharma
2.5552 of 5 stars
-56.8%$14.79MN/A-0.3942Earnings Report
Edesa Biotech
2.5206 of 5 stars
-24.8%$14.65MN/A0.0016Negative News
VBI Vaccines
0.9686 of 5 stars
N/A-78.9%$18.07M$8.68M0.00131Analyst Forecast
News Coverage
Gap Up

Related Companies and Tools

This page (NASDAQ:TRAW) was last updated on 5/21/2024 by Staff

From Our Partners